Compare Crispr Therapeutics AG (CRSP) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Teucrium Soybean Fund — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Teucrium Soybean Fund trades at $25.28. The key difference: Teucrium Soybean Fund is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | SOYB | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $76.78 | $25.36 |
52-Week Low | $44.34 | $21.07 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
SOYB trades at $25.33, up 0.64% on the day, with a bullish technical outlook from moving averages but neutral oscillators. The stock lacks disclosed financial ratios, and recent news highlights potential tailwinds from agricultural trade developments, including China's pledge to buy $17 billion of U.S. crops annually through 2028, which could benefit related sectors.
The stock's upside is supported by positive technical momentum and sector-specific catalysts, though the absence of fundamental data limits valuation clarity. Risks include reliance on agricultural market stability and potential volatility from commodity price swings, requiring careful assessment of upcoming earnings and guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
